Amgen Inc

“Amgen is a high-cash-flow biologics franchise with real but narrowing moats, burdened by $45B net debt from the Horizon acquisition and facing irreversible biosimilar erosion on ~30% of revenue. The 14.6x forward P/E is optically low but inflated by $3B in Horizon amortization, and the $10.7B IRS dispute adds meaningful tail risk. MariTide's obesity program is the primary long-term rerating catalyst, but it remains a binary Phase 3 bet against an entrenched Novo/Lilly duopoly. At $342, the risk/reward is unattractive — fair value with no margin of safety is not an investment; it is a coin flip on MariTide dressed up as a value trade.”